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Monoclonal antibodies represent the fastest growing class of biopharmaceutical products and have a host 
of applications in medical research, diagnosis, therapy, and basic science. The production of recombinant 
monoclonal antibodies has revolutionized the generation of immunoglobulins, and their use represents 
a strategic breakthrough, affecting the global pharmaceutical market for therapeutic proteins. In the 
present work, a review of scFv, and the number of related patents, has been carried out. The results show 
that several countries have scFv patents, most notably the United States, China and United Kingdom. 
The target of these scFv antibodies was also assessed and the results demonstrate that most are directed 
toward cancer therapy.
Uniterms: Monoclonal antibodies. Recombinant antibodies. scFv. Biopharmaceuticals.
Anticorpos monoclonais representam a classe de maior crescimento em produtos de biofármacos e 
possuem várias aplicações em pesquisa médica, diagnóstico, terapias e ciência básica. A produção de 
anticorpos monoclonais recombinantes revolucionou a geração de imunoglobulinas e sua utilização 
implica em avanço estratégico, afetando o mercado farmacêutico global de proteínas terapêuticas. 
No presente trabalho, uma revisão sobre scFv e a relação do seu número de patentes foi analisada. Os 
resultados mostram que vários países apresentam patentes de scFv com destaque para os Estados Unidos, 
China e Reino Unido. Os alvos desses anticorpos também foram avaliados e as análises revelaram que 
a maioria é destinado a terapias contra o câncer.
Unitermos: Anticorpos monoclonais. Anticorpos recombinantes. scFv. Biofármacos.
INTRODUCTION
Due to their extreme specificity, monoclonal anti-
bodies (mAbs) have been pivotal for analytical advances 
in the field of medical research, diagnosis, therapy, and 
basic science. In 1975, Kohler and Milstein published 
their seminal malignancies manuscript on hybridoma 
technology, enabling the production of mouse mAbs. 
Since then, technical advances have allowed the transi-
tion from mouse, via chimeric and humanized, to fully 
human mAbs (Dubel, 2007; Lonberg, 2005), with a re-
duction in potentially immunogenic mouse components. 
In this aspect, the use of immunoglobulins submitted to 
genetic engineering has now become commonplace and 
represents a strategic breakthrough, affecting the global 
biopharmaceutical market for therapeutic proteins. This 
has led to mAbs achieving marked successes in clini-
cal settings (Reichert et. al., 2005; Waldmann, 2003). 
Indeed, the US Food and Drug Administration has now 
approved more than 20 mAbs, and more than 150 other 
mAbs are currently undergoing clinical trials (Reichert, 
Dewitz, 2006).
The use of monoclonal antibodies (mAb) in biome-
dical research has been, and will continue to be, important 
for the identification of proteins, carbohydrates, and nu-
cleic acids. Their use has led to the elucidation of many 
molecules that control cell replication and differentiation, 
advancing our knowledge of the relationship between 
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molecular structure and function. These advances in basic 
biologic sciences have improved our understanding of 
the host response to infectious-disease agents and toxins 
produced by these agents, response to transplanted organs 
and tissues, to spontaneously transformed cells (tumors), 
and to endogenous antigens (involved in autoimmunity). 
In addition, the exquisite specificity of mAb allows them 
to be used in humans and animals for disease diagnosis 
and treatment.
The present work originated from a survey on scFv 
patents, conducted in order to identify the leading coun-
tries in the development of technologies involving scFvs. 
The results were obtained through the mapping of patent 
records on scFv, and of the applications of these antibo-
dies in different countries. Another aim of this study was 
to identify scFvs approved to date for therapy, and those 
undergoing clinical trials.
Monoclonal antibodies: evolution and 
perspectives
Antibodies are glycoproteic molecules originating 
from B cells, which circulate through blood and lym-
ph. They are responsible for the remarkable ability to 
detect, locate, recognize, bind to an antigen, inactivate 
it or facilitate its elimination. Each antibody molecu-
le has a unique structure that allows specificity to its 
corresponding antigen. All of them possess the same 
general structure and are also called immunoglobulins 
(Silverton, 1977).
The first experimental evidence of the use of anti-
bodies was proposed by Emil Adolf Von Behring, who 
demonstrated the use of immunoglobulins to neutralize 
the diphtheric protein, triggering a revolution in scientific 
thinking of the time (Nobelpreis, 2009).
Antibodies represent an important category of pro-
teins, not only for their ability to recognize epitopes with 
high affinity and specificity, but also for their stability and 
engineering potential. Despite the potential application 
of the monoclonal antibodies produced by hybridoma 
technology, their use is limited by their high toxicity. 
mAbs are proteins normally produced from cells of mice 
or rats which, when injected into human patients, even-
tually generate an immune response against the foreign 
protein, known as a HAMA response (human antimouse 
antibodies). HAMA is characterized by the development 
of antibodies by the host, causing an immune response 
against the administered antibodies, culminating in their 
neutralization or in a strong immune reaction. This res-
ponse was a great disappointment for scientists, because it 
can cause hypersensitivity reactions, such as anaphylaxis 
and Serum Sickness. Moreover, these antibodies are only 
effective during the first administration. In subsequent 
administration, the immune system will be prepared to 
destroy them before promoting their function (Schroff 
et al., 1985; Shawler et al., 1985). This effect is similar 
to that observed in the use of heterologous antivenoms. 
Therefore, these responses of the individual against the 
administration of heterologous protein currently limit the 
use of these drugs.
Applications using genetic engineering techniques 
for genes encoding the variable regions (V) and constant 
(C) monoclonal antibodies, are considered the latest ge-
neration of drugs of recombinant antibodies. The process 
consists of antibody genetic manipulation to make the 
structure of amino acids more closely resemble the struc-
ture found in human antibodies, thereby reducing adverse 
reactions and HAMA response in patients. A wide variety 
of molecules can be obtained by this process, which 
allows different functions. Latterly, the combination of 
hybridoma technology, recombinant DNA technology and 
the Phage Display technique has allowed the production 
of antibodies with desirable specificity and affinity (Rees 
et al., 1994).
The Phage Display technique was discovered in 
1985 by Smith, who developed libraries of peptides on the 
surface of phages. It is a widely used and well-established 
technique for the selection and production of antibodies 
expressed in libraries (Maynard, Georgiou, 2000). Using 
this technique, it is possible to mimetize the strategy used 
by the humoral immune system to produce completely hu-
man antibodies or fragment antibodies while waiving the 
immunization process or the construction of hybridomas 
(Roque et al., 2004).
It has been 34 years since the first generation of 
monoclonal antibodies from B cells of hybridomas of 
mice (Kohler, Milstein, 1975) and 23 years since the fist 
approval by the FDA of the use of monoclonal antibodies 
as therapy (OKT®3, Johnson&Johnson). As with OKT®3 
(muromonab), the first monoclonal antibodies were pro-
duced exclusively in mouse cells. However, there was an 
obstacle regarding the use of this discovery. Because the 
antibodies were of animal origin – mice –, their use in 
humans caused the HAMA response.
Therefore, scientists strove for years to substitute 
parts of murin antibodies (momab) with human compo-
nents (Figure 1). Depending on the way these antibo-
dies are altered, they can be called chimeric antibodies 
(ximab) or humanized antibodies (zumab). Currently, 
some technologies, such as Phage Display technology, 
allow the production of totally human antibodies (umab) 
(Ballow, 2005).
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Research has also been developed using fragments 
of these antibodies instead of the entire molecule. Because 
entire antibodies are large molecules (~150 kDa), small 
fragments derived from IgG can be constructed to stop the 
antigen-binding activity, such as the minibody fragments 
Fab, scFv and Fv, or to block the effectors’ functions, such 
as the constant fragment Fc (Figure 1). These small antibo-
dies (~15-55 KDa) can be equipped with radioisotopes or 
other markers that may be used to locate the target antigen 
or employed in therapy (Kozak et al., 1985).
Among the most studied recombinant antibodies 
are the Fab (fragment antigen binding) and the scFv (sin-
gle chain fragment variable). The single chain fragments 
(scFv) have been used in both therapy (Chester, Hawkim, 
1995) and diagnoses, and have shown advantages over 
conventional and monoclonal antibodies (Lorimer et 
al., 1996; Turner et al., 1997; Wintlow, Filppula, 1991). 
Such molecules were proven to have rapid blood circu-
lation, since patients treated with scFv presented good 
localization of the molecules only one hour after their 
injection (George et al., 1996). They also present good 
penetration in tissues, low immunogenicity in theory, 
low retention in the kidneys and other non-target organs, 
better penetration in target tumors, are easily construc-
ted, have low commercial cost in large-scale production 
(Wintlow, Filppula, 1991) and, moreover, it is possible 
to restructure them in order to improve their activity and 
production (Turner et al., 1997).
As a result, many institutions worldwide have been 
carrying out research on scFv antibody fragments, such 
as Dana Farber Cancer Institution (US), Sloan Kettering 
Cancer Institution (US), University of Zurich (CN), 
Northeast Normal University (CN), Nanjin Normal 
University (CN), Tianjin Medical University (CN), Seoul 
National University Industry Foundation (KR), Oakland 
University (US), University Vanderbilt (US), Institut 
National de la Santé e de la Recherche Médicale (FR), 
Jandrot-Perrus Martine (FR), University of California 
(US), Avicore Biotechnology (KR), Unilever PLC (GB), 
and Unilever NV (NL).
Therefore, assessing scFv patents can be used as a 
marker of the use of this new class of biopharmaceuticals 
and also indicate the countries and institutions which 
have been contributing to the future of antibody therapy 
in the world.
Intellectual property
Intellectual property is the general term that ex-
presses the right of inventors or those responsible for any 
intellectual production, to receive, at least for a certain 
period of time, reward for their inventions. According 
to the Worldwide Intellectual Property Organization 
(WIPO), inventions, literary and artistic work, symbols, 
names, images, designs and models used in commerce, 
all constitute intellectual property. Intellectual property 
comprises two major areas: industrial property (patents, 
trademarks, industrial design, geographic indications and 
cultivar protection) and copyright (literary and artistic 
work, computer programs, Internet domains and intangible 
culture heritage (Wipo, 2010). Intellectual property makes 
it possible to transform knowledge, in principle an almost 
a public asset, into a private asset, and constitutes the link 
between knowledge and market (Lastres, Ferraz, 1999).
FIGURE 1 - Types and fragments of monoclonal antibodies.
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In short, the filing of a scFv patent means that this 
fragment antibody is a biopharmaceutical, or has the po-
tential to be used as such.
METHODOLOGICAL ASPECTS
The present work entailed quantitative research on 
data available from public access patent banks. In order to 
carry out this study, mapping of the number of worldwide 
published patents* containing scFv in their title and/or 
abstract was done. The research was performed using the 
free-of-charge database esp@cenet (http://ep.espacenet.
com). The first search on the patent banks occurred in 
July 2009.
In addition, the registers of EPO - European Patent 
Office (http://www.epoline.org/portal/public/registerplus) 
and USPTO - United States Patent and Trademark Office 
(http://uspto.gov) were used in order to obtain more details 
about the patents.
The “Original Document” of each patent was used 
in the detailed analysis of the requested patents indicated 
by the mapping. The “Original Document” is a document 
published by the Intellectual Property (IP) office and 
contains in-depth information about the record of the 
analyzed patents.
RESULTS AND DISCUSSION
The results of the search yielded 315 scFv patents 
published in the period from January 1996 to July 2009. 
Figure 2 shows the countries of origin of applicants and 
the number of patents requested by each country.
Figure 2 shows that the United States has the most 
requested scFv patents (n=90), followed by China (n=42) 
and the United Kingdom (n=30). Subsequently, the year of 
patents requests of the prominent countries were analyzed 
(the United States, China and the United Kingdom, repre-
sented by Figure 3).
Subsequently, the main targets of patent records 
of the prominent countries were assessed, as shown in 
Figure 4.
The pharmaceutical industry produces a broad variety 
of chemical, natural and biotechnological products. This field 
is essentially based on technological innovation and uses in-
tellectual property in the form of patents in order to own rights 
to innovations attained through high costs in R&D (research 
and development). These patents grant market exclusivity and 
generate high profits (Fardelone, Branchi, 2006).
This work presents a mapping of patents of scFv 
antibody fragments. The results show that many countries 
such as the United States, China, the United Kingdom, 
*Published patents are those which have been requested and published after the secrecy period (18 months approximately) and include granted, non-granted and 
pending patents.
FIGURE 2 - Number of scFv patents requested by country of origin of applicants (* Patents requested by two countries (1 Japan/
United States, 2 Germany/United States, 1 United Kingdom/Austria, 1 United Kingdom /Switzerland, 1 United Kingdom /United 
States, 1 United States/China, 1 United Kingdom/Germany, 1 Italy/Netherlands, 1 Italy/Slovakia, 1 Switzerland/Austria, 1 Cuba/
Netherlands, 2 United Kingdom/Netherlands, 1 Israel/Poland, 1 France/Canada, 1 Sweden/Australia, 1 Russia/Switzerland). 
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Germany, Japan, Switzerland, Canada, South Korea, 
France, Israel, Italy, New Zealand, Belgium, Mexico, 
Australia, Hong Kong, Holland, Ireland, Cuba, Ukraine, 
Sweden and Georgia hold scFv patent records (Figure 2). 
The United States, China and the United Kingdom are the 
prominent patent-holding countries, in other words, they 
held the greatest number of published patents in the world. 
A patent study of these countries was therefore carried out, 
verifying year of publication, the targets of the antibodies 
and, finally, the application of the knowledge involving 
scFv production.
The United States was found to have the most records 
(Figure 3), with 90 patents containing scFv in their titles 
and/or abstract. This finding was expected since the country 
invests heavily in R&D (research and development) directed 
toward pharmaceuticals and is considered a world power in 
S&T (science and technology). The majority of pharmaceu-
tical product sales occur essentially in the triad comprising 
the United States, Japan and Europe, together accounting 
for 88% of all global commercial transactions. The United 
States are the main market, representing 45% of the sales in 
a 643-billion-dollar global market (Radaelli, 2008).
In the United States, several antibodies have been 
authorized by the FDA and, although no scFvs have been 
approved to date, many scFvs and subtypes are the focus 
of research (Gupta et al., 2010) or are undergoing clinical 
testing (Table I).
The technology of scFv antibodies in the United States, 
FIGURE 3 - Distribution of number of scFv patents by year for countries with most patent requests.
FIGURE 4 - Main targets of scFv patents in countries with most requests.
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based on analysis of the patentees (an inventor or institu-
tion, such as companies, universities, research institutes), is 
equally distributed around the country. Several institutions are 
involved, such as the Dana Farber Cancer Institution, Sloan 
Kettering Cancer Institution, Oakland University, University 
Vanderbilt, Biogen Idec, Amgen, Genencor International, 
Mccormick Alison and Nox Technologies among others. 
Sometimes the inventor personally requested the patent in 
the country, but the majority of the patents were requested by 
an institution. The United States have recorded scFv patents 
since 1996 (n=1) and there was a great increase in these pa-
tents in 2003 (n=12), as shown in Figure 3.
The study of the targets of scFv antibodies over the 
years (Figure 4) revealed that most patents recorded in the 
United States involved therapies against cancer (n=29), 
followed by production methods of these antibodies 
(n=18). The others were aimed at treatment of autoimmu-
ne diseases, immunomodulation, agricultural and animal 
husbandry plagues, viruses and bacteria, among other 
highly heterogeneous targets (n=39). In this sense, the 
knowledge of scFv antibodies is directed toward different 
therapies and is distributed among research groups all over 
the country. The perspective is that recombinant antibody 
technology is set to further increase in the USA, since this 
technology is linked to a new class of medications, namely, 
the biopharmaceuticals.
China was ranked in second position (Figure 3) with 
42 patents. This position was predictable, for according to 
a 2006 report by the OECD (Organization for Economic 
Cooperation and Development), China was set to surpass 
Japan in investments in 2009, to attain the second position, 
after the United States.
According to latest estimates, China will invest about 
136 billion dollars this year in R&D, slightly more than 
Japan (130 billion) but still a lot less than the USA, which 
is the leader in the area, investing 330 billion dollars a year. 
Although a few Chinese scFv patents were recorded by the 
inventors themselves, most were recorded by companies 
and universities, such as Beijing Abt Genetic Engineering 
Technology, Chengdu Photon Biotechnology, Institute 
of Medical Biotechnology, Military Medical University, 
Nanjing Normal University, Northeast Normal University, 
Shangai Cp Guojian Pharmaceutical, Shenyang Applied 
Ecology Institute, Tianjin Medical University, Chugai 
Pharmaceutical (JP), Britain Hills Biomolecule (UK), 
Terubion Pharmacy (US), among others. The quantity of 
patents recorded by a single company or university did 
not exceed three. In other words, none stood out more 
than the others. The scFv patents have been published in 
China since 1999, with a great number of recent records in 
2008, as shown in Figure 3. Analyzing the targets of scFv 
antibodies patented by China (Figure 4), most are directed 
toward cancer therapy, a small number for treating autoim-
mune diseases (n=2) while the remaining patents are aimed 
at other applications (n=17). Therefore, the data regarding 
Chinese scFv patents indicates that knowledge is being 
generated equally throughout the country, and there is no 
single outstanding company or university. Moreover, the 
target of these monoclonal antibodies is directed mainly 
toward cancer therapy.
The United Kingdom is made up of England, Sco-
tland, Wales and Northern Ireland although some sources 
refer to England, Scotland, Wales and Northern Ireland as 
countries. However, even though these possess a certain 
degree of autonomy, they are not independent, being ruled 
over by the British Parliament in London. Although ranked 
third for scFv patent applications (n=30), as shown in 
Figure 3, the United Kingdom is considered a worldwide 
leader in innovation. Among the 30 scFv patents requested 
by the UK, 10 were recorded by Cambridge Antibody Te-
TABLE I - scFvs undergoing clinical test
Indication Brand Name Target Stage Reference/website
Melanoma (scFv) SGN-17 P97 antigen Preclinical http://www.seagen.com/
Breast cancer (scFv) F5 scFv-PEG 
Immunoliposome
Her2 Preclinical Biotchnol. Prog. 21, 
221-232 (2005)
Ovarian and breast cancer 
(diabody)
C6.5K-A Her2/Neu Preclinical Cancer Res. 64, 
6200-6206 (2004)
Antiangiogenesis and 
atherosclerotic plaque imaging 
(diabody)
L19 L19–g IFN EDB domain of 
fibronectin
Preclinical Int. J. Cancer 116, 
304-313 (2005)
Colorectal cancer imaging 
(diabody)
T84.66 CEA Preclinical Protein Eng. Des. Sel. 
17, 21-27 (2004)
B-cell tumors (bispecific scFv) BiTE M103 CD19 and CD3 Phase 1 http://www.micromet.de/
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chnology (CAT) 5 of which were recorded in association 
with the Medical Research Council (MRC). The other 
20 patents were recorded by several different patentees, 
with no distinction among them. CAT is one of the largest 
biopharmaceutical companies in the UK and a leader in 
monoclonal antibody therapy, which explains the high 
number of scFv patents requested by the group. Founded 
in 1990, its headquarters is located in Granta Park (Cam-
bridge). Using advanced technologies for the isolation of 
monoclonal human antibodies, it develops numerous and 
different antibodies independently, or in collaboration 
with, other researchers. In 2007, there was an integration 
of MedImmune, CAT and AstraZeneca´s. This integration 
is currently called MedImmune (www.medimmune.com). 
Another interesting fact was the higher number of recorded 
patents in 2003, 2007 and 2008 (Figure 3). Analysis of 
the targets of scFv patents recorded throughout the years 
(Figure 4) showed that a large number of patents involved 
the process of antibody fragment production or, in other 
words, were related to methodology (n=7). Seven of these 
were recorded by Cambridge Antibody Technology (CAT) 
in association with the Medical Research Council (MRC– 
www.mrc.ac.uk). The same number of patents (n=7) was 
also found aimed at the treatment of cancer. The target of 
the remaining patents (n=16) was diverse. In general, it is 
possible to conclude that the scFv technology in the United 
Kingdom is concentrated in England (Cambridge) and 
that attention should be focused on MedImmune. Also, in 
the past, the therapeutic target of these antibodies was the 
development of technology to produce these antibodies, 
whereas focus has now shifted to cancer therapy.
Based on this data, we can conclude that the publi-
shed scFv patents in the world are most focused on the-
rapies directed at tumors, whereas a minority is focused 
on autoimmune diseases, similar to the pattern observed 
in the 3 countries individually. The reason why these 
applications are focused on cancer therapy is explained 
by the increased incidence of these diseases and the great 
difficulty fighting them.
In years to come, the market will be flooded by these 
latest generation antibodies. Moreover, the technology of 
monoclonal antibody humanization is linked to a new class 
of medications, namely, the biopharmaceuticals. These 
can be directed toward the treatment of important diseases 
such as cancer, infections and clinical conditions including 
sepsis, transplant rejection, AIDS and autoimmune disea-
ses (Hon, 2009). The use of immunoglobulins submitted 
to genetic engineering has become commonplace and 
represents a strategic advancement involving the global 
biopharmaceutical market of therapeutic proteins (Rosen 
et al., 1983).
This study showed an increase in scFv patent records 
and also revealed the applications of the resultant research. 
Unfortunately, many studies involving this technology did 
not require patents, precluding a detailed analysis of the si-
tuation worldwide. In Brazil, for example, much promising 
research using scFv antibodies has been conducted, leading 
to numerous publications in journals (Caldas et al, 2000; 
Maranhão, Brígido, 2000; Oliveira et al., 2008; Pignatari et 
al., 2007; Tamarozzi et al., 2006). Nevertheless, no publi-
shed patent related to this research work was found.
Perspectives
Single-chain antibodies are highly promising in new 
therapeutic targets directed toward diseases such as cancer. 
Their use has grown significantly over the past few years, 
and with continued research, new biopharmaceuticals pro-
ducts will soon be available for use in clinical medicine.
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